NASDAQ:UTHR United Therapeutics - UTHR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. $252.80 -6.68 (-2.57%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$252.30▼$262.7750-Day Range$252.80▼$280.4352-Week Range$158.38▼$283.09Volume500,781 shsAverage Volume317,864 shsMarket Capitalization$11.52 billionP/E Ratio17.20Dividend YieldN/APrice Target$283.64 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability United Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.58 Rating ScoreUpside/Downside12.2% Upside$283.64 Price TargetShort InterestHealthy2.93% of Float Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment-0.15Based on 11 Articles This WeekInsider TradingSelling Shares$63.21 M Sold Last QuarterProj. Earnings Growth13.03%From $16.58 to $18.74 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.48 out of 5 starsMedical Sector141st out of 1,028 stocksPharmaceutical Preparations Industry60th out of 501 stocks 2.3 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.58, and is based on 9 buy ratings, 1 hold rating, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $283.64, United Therapeutics has a forecasted upside of 12.2% from its current price of $252.80.Amount of Analyst CoverageUnited Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.93% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in United Therapeutics has recently decreased by 1.50%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 1.0 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for United Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $63,206,270.00 in company stock.Percentage Held by Insiders12.40% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.63% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 13.03% in the coming year, from $16.58 to $18.74 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 17.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.14.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 17.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 105.82.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 1.84. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About United Therapeutics (NASDAQ:UTHR) StockUnited Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.Read More Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Stock News HeadlinesFebruary 3, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Sells $182,931.00 in StockFebruary 2, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $2,092,000.00 in StockFebruary 4, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…February 1, 2023 | americanbankingnews.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 8,000 Shares of StockJanuary 30, 2023 | finance.yahoo.comThose who invested in United Therapeutics (NASDAQ:UTHR) three years ago are up 172%January 29, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $2,113,680.00 in StockJanuary 28, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) Receives $283.64 Average Target Price from BrokeragesJanuary 27, 2023 | americanbankingnews.comMartine A. Rothblatt Sells 8,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockFebruary 4, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…January 21, 2023 | finance.yahoo.com10 Best Healthcare Stocks For RecessionJanuary 19, 2023 | finance.yahoo.comAfter Plunging -5.18% in 4 Weeks, Here's Why the Trend Might Reverse for United Therapeutics (UTHR)January 11, 2023 | markets.businessinsider.comAnalyst Ratings for United TherapeuticsJanuary 9, 2023 | finance.yahoo.comLiquidia inks $100M financing agreement amid patent disputeJanuary 6, 2023 | finance.yahoo.comUnited Therapeutics Corporation's (NASDAQ:UTHR) Intrinsic Value Is Potentially 98% Above Its Share PriceJanuary 5, 2023 | finance.yahoo.comIBD Stock Of The Day United Therapeutics Is Braving Competition, And Eyeing Two EntriesJanuary 2, 2023 | finance.yahoo.comUnited Therapeutics Corporation to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 22, 2022 | finance.yahoo.comThe Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli LillyDecember 21, 2022 | bizjournals.comDurham drugmaker names new CEO at pivotal junctureDecember 16, 2022 | finance.yahoo.comThe Zacks Analyst Blog Highlights LPL Financial Holdings, Enphase Energy, United Therapeutics, ShockWave Medical and ChampionXDecember 9, 2022 | americanbankingnews.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells 1,010 Shares of StockDecember 6, 2022 | msn.comMorgan Stanley Maintains Overweight Rating for United Therapeutics: Here's What You Need To KnowDecember 5, 2022 | seekingalpha.comUnited Therapeutics draws Sell at Goldman on lack of growth driversDecember 5, 2022 | markets.businessinsider.com6 Analysts Have This to Say About United TherapeuticsDecember 3, 2022 | finance.yahoo.comWhy Is United Therapeutics (UTHR) Up 3.8% Since Last Earnings Report?December 1, 2022 | finance.yahoo.comUnited Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy?November 25, 2022 | seekingalpha.comUnited Therapeutics: Stock With Strong Growth And Attractive ValuationNovember 11, 2022 | msn.comUTHR vs. CORT: Which Stock Should Value Investors Buy Now?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Company Calendar Last Earnings11/03/2021Today2/04/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees965Year Founded1996Price Target and Rating Average Stock Price Forecast$283.64 High Stock Price Forecast$375.00 Low Stock Price Forecast$203.00 Forecasted Upside/Downside+12.2%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$14.70 Trailing P/E Ratio17.20 Forward P/E Ratio15.25 P/E Growth1.84Net Income$475.80 million Net Margins38.03% Pretax Margin49.05% Return on Equity16.63% Return on Assets12.95% Debt Debt-to-Equity Ratio0.18 Current Ratio9.68 Quick Ratio9.39 Sales & Book Value Annual Sales$1.86 billion Price / Sales6.19 Cash Flow$11.37 per share Price / Cash Flow22.23 Book Value$87.90 per share Price / Book2.88Miscellaneous Outstanding Shares45,577,000Free Float39,925,000Market Cap$11.52 billion OptionableOptionable Beta0.63 Social Links Key ExecutivesMartine A. RothblattChairman & Chief Executive OfficerMichael Ian BenkowitzPresident & Chief Operating OfficerJames Christopher EdgemondTreasurer, Chief Financial & Accounting OfficerPaul A. MahonSecretary, Executive VP & General CounselDewey SteadmanHead-Investor RelationsKey CompetitorsIonis PharmaceuticalsNASDAQ:IONSMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSAmicus TherapeuticsNASDAQ:FOLDBioMarin PharmaceuticalNASDAQ:BMRNView All CompetitorsInsiders & InstitutionsEmerald Advisers LLCBought 1,189 shares on 2/3/2023Ownership: 0.207%Hancock Whitney CorpSold 360 shares on 2/3/2023Ownership: 0.026%EFG Asset Management North America Corp.Sold 1,787 shares on 2/3/2023Ownership: 0.023%Fisher Asset Management LLCBought 4,419 shares on 2/3/2023Ownership: 0.010%Aveo Capital Partners LLCSold 45 shares on 2/3/2023Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions UTHR Stock - Frequently Asked Questions Should I buy or sell United Therapeutics stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UTHR shares. View UTHR analyst ratings or view top-rated stocks. What is United Therapeutics' stock price forecast for 2023? 12 equities research analysts have issued 12 month price targets for United Therapeutics' shares. Their UTHR share price forecasts range from $203.00 to $375.00. On average, they predict the company's share price to reach $283.64 in the next year. This suggests a possible upside of 12.2% from the stock's current price. View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts. How have UTHR shares performed in 2023? United Therapeutics' stock was trading at $278.09 at the start of the year. Since then, UTHR shares have decreased by 9.1% and is now trading at $252.80. View the best growth stocks for 2023 here. When is United Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our UTHR earnings forecast. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings results on Wednesday, November, 3rd. The biotechnology company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.37 by $0.05. The biotechnology company had revenue of $444.70 million for the quarter, compared to the consensus estimate of $421.45 million. United Therapeutics had a trailing twelve-month return on equity of 16.63% and a net margin of 38.03%. The firm's quarterly revenue was up 17.0% on a year-over-year basis. During the same period in the previous year, the business posted $3.84 earnings per share. What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE). What is United Therapeutics' stock symbol? United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR." Who are United Therapeutics' major shareholders? United Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (1.32%), Poplar Forest Capital LLC (0.33%), Wedge Capital Management L L P NC (0.31%), Allspring Global Investments Holdings LLC (0.27%), Tobam (0.24%) and Emerald Advisers LLC (0.21%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is United Therapeutics' stock price today? One share of UTHR stock can currently be purchased for approximately $252.80. How much money does United Therapeutics make? United Therapeutics (NASDAQ:UTHR) has a market capitalization of $11.52 billion and generates $1.86 billion in revenue each year. The biotechnology company earns $475.80 million in net income (profit) each year or $14.70 on an earnings per share basis. How many employees does United Therapeutics have? The company employs 965 workers across the globe. How can I contact United Therapeutics? United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291. This page (NASDAQ:UTHR) was last updated on 2/4/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.